Bioinsider Launches COVID-19 Virtual Meeting Series

BOSTON, Massachusetts – Bioinsider LLC (Bioinsider), a company dedicated to creating a quality, unbiased virtual meeting platform for communication among the scientific, policymaker and business communities, has opened registration and a call for speaker proposals for its four-part virtual meeting series, Together as One COVID-19 Series. The series begins Thursday, June 18, 2020 with “Diagnostic Landscape for COVID-19,” which will focus on molecular, serology, rapid testing, and how to properly handle the pandemic with the current testing capacity.

The ‘Together as One’ COVID-19 Series will provide insights on diagnostics, vaccines, therapeutics, and life after Coronavirus. All net proceeds from the events will go to the COVID-19 Solidarity Response Fund for World Health Organization.

“Sharing new scientific findings and important perspectives from innovators and decision-makers has never before been so crucial in our industry,” said Bioinsider LLC Founder and CEO Dr. Ngoc ‘Emily’ Le. “With the current state of things, in-person meetings are no longer possible. This is where Bioinsider comes in. Each virtual event will feature presentations from thought leaders, speed networking sessions, and face-to-face breakout brainstorming sessions. Our objective is to host virtual events that allow attendees and participants to create connections, enrich knowledge, foster collaborations, drive the success of their research, and spark innovations.”

Each meeting in the Together as One COVID-19 Series is available both academic/non-profit and commercial attendees, $25 and $50 respectively. Face-to-face breakout sessions will be limited to 15 participants each and are available for an additional cost of $25. Members of the scientific and medical communities are encouraged to register early, as speed networking and breakout sessions are available on a first-come, first-serve basis. To register, visit www.bioinsidernetwork.com/registration.

Speaker and sponsorship opportunities are also available. For details on submitting a speaker proposal or becoming a sponsor, visit www.bioinsidernetwork.com.

About Bioinsider

Founded in 2020, Bioinsider LLC is a group of like-minded individuals dedicated to creating a quality-driven, unbiased virtual meeting platform for communication among the scientific community, policymakers, and business leaders. The goal of these events is to create connections, enrich knowledge, foster collaborations, drive the success of the research, and spark innovations. For more information, visit bioinsidernetwork.com.

About Dr. Ngoc ‘Emily’ Le, Founder and CEO, Bioinsider

Dr. Le received her Doctor of Philosophy in Chemistry from the University of Massachusetts, Amherst, and spent years working as a content conference producer and led the product development analytics group at Cambridge Healthtech Institute. She has nine years of experience working with academic, healthcare, biopharma, and executive professionals in technical-scientific and business settings. She has diverse knowledge in diagnostics, drug development, commercial strategy, and various therapeutic areas, including immuno-oncology, and gene and cell therapies.

Share on linkedin
LinkedIn
Share on twitter
Twitter
Share on facebook
Facebook
Share on xing
XING
Share on email
Email

Therapeutics Pipeline for COVID-19

Get the latest updates, interviews and receive special offers

Pre-register Today!

Ralph Rogers, MD

Assistant Professor of Medicine, Clinician Educator, Infectious Diseases, Warren Alpert Medical School of Brown University

Ralph Rogers, MD is an infectious disease specialist at the Lifespan Cancer Institute. He earned his medical degree from The Warren Alpert Medical School of Brown University where he also completed his residency and fellowship in infectious diseases. Dr. Rogers is Assistant Professor of Medicine, Clinician Educator Division of Infectious Diseases Warren Alpert Medical School of Brown University. He is a member of the Infectious Diseases Society of America (IDSA), the American Society for Microbiology (ASM) and the American Society of Transplantation (AST).

John Sninsky, PhD

Consultant, Translational Sciences

John J. Sninsky, PhD is a translational medicine consultant with deep understanding of diagnostics and diagnostics paired with medicine intervention. John has served in senior management positions in small and large CLIA service laboratories and in vitro diagnostic kit companies including Cetus, Roche Molecular Systems, Celera, Quest and CareDx. He was a member of the pioneering Cetus team that developed and optimized PCR technology for research and diagnostic use; specifically, the virology team developed the HIV, HTLV, HPV, HCV and HBV PCR assays. John put in place a surveillance initiative for viral variants and presented at the first FDA PMA advisory meeting for HIV PCR approval.

Timothy J. O’Leary, MD, PhD

Adjunct Professor, Pathology, University of Maryland School of Medicine; Former Chief Research and Development Officer, Veterans Affairs

Timothy O’Leary, MD, is Adjunct Professor of Pathology at the University of Maryland and served as Chief Research and Development Officer (CRADO) of the Department of Veterans Affairs from 2013-2015. He holds a doctorate in physical chemistry from Stanford University and a medical degree from the University of Michigan.

He is certified in anatomic pathology by the American Board of Pathology and in molecular genetic pathology by the American Board of Pathology and the American Board of Medical Genetics. Prior to his VA service, O’Leary chaired the Department of Cellular Pathology and Genetics at the Armed Forces Institute of Pathology for more than 15 years. He joined VA in 2004 and served as Director of Biomedical Laboratory Research and Development, Director of Clinical Sciences Research and Development, and Deputy CRADO prior to his appointment as CRADO. O’Leary also served as a reserve member of the Public Health Service Commissioned Corps from 1979 to 2010, serving two tours on active duty. His research interests include genomics, proteomics, and ultrasensitive detection of biological toxins. He has served on numerous federal panels and advisory committees, including the Health and Human Services Clinical Laboratory Improvement Advisory Committee and the Food and Drug Administration Hematology and Devices Panel. O’Leary, the holder of four patents, has authored or co-authored more than 190 journal articles and numerous book chapters and technical reports. He is a past president of the Association for Molecular Pathology and served as editor-in-chief for the Journal of Molecular Diagnostics.